Published in Curr Drug Targets on January 01, 2015
Systematic review and meta-analysis of lactose digestion, its impact on intolerance and nutritional effects of dairy food restriction in inflammatory bowel diseases. Nutr J (2016) 0.77
Influence of diet on the gut microbiome and implications for human health. J Transl Med (2017) 0.75
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert Rev Gastroenterol Hepatol (2017) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J (2006) 17.53
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
Platelet activation and atherothrombosis. N Engl J Med (2007) 6.18
Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 6.00
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 5.87
Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet (2010) 5.63
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature (1998) 5.21
The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol (2012) 3.88
Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation (2002) 3.60
Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol (1999) 3.44
Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (1998) 3.31
Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol (2009) 3.05
Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation (2006) 2.70
Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut (2004) 2.55
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 2.38
Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut (2012) 2.34
Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation (2000) 2.27
Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res (2007) 2.22
New risk factors for atherosclerosis and patient risk assessment. Circulation (2004) 2.07
C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension (2004) 1.99
The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol (2007) 1.91
Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol (2011) 1.88
Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr (2007) 1.84
Role of cytokines in inducing hyperlipidemia. Diabetes (1992) 1.74
Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J (2012) 1.71
Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology (1994) 1.65
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol (2004) 1.59
Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke (2007) 1.56
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut (2003) 1.56
Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol (2007) 1.50
Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol (2008) 1.47
Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol (2009) 1.47
Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation (1999) 1.44
Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut (1989) 1.35
Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci (1995) 1.29
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology (2010) 1.23
Inflammation alters HDL composition and function: implications for HDL-raising therapies. Pharmacol Ther (2012) 1.23
Infection as a risk factor for infarction and atherosclerosis. Ann Med (1991) 1.22
Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int J Cardiol (2005) 1.20
Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum (1997) 1.20
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol (2005) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res (2007) 1.17
Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis (2011) 1.17
Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol (2011) 1.17
Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol (2007) 1.16
Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study. Inflamm Bowel Dis (2010) 1.14
Formation of platelet-leukocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.12
Is inflammatory bowel disease a risk factor for early atherosclerosis? Angiology (2009) 1.06
No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin Gastroenterol Hepatol (2011) 1.05
Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J Crohns Colitis (2013) 1.04
Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev (2003) 1.03
TNF alpha production to TLR2 ligands in active IBD patients. Clin Immunol (2006) 1.02
Infections may be causal in the pathogenesis of atherosclerosis. Am J Med Sci (2012) 1.02
Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism (2006) 1.00
Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2008) 1.00
Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease. J Inflamm (Lond) (2014) 1.00
Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr (2000) 0.99
Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther (2011) 0.97
Risk of venous thromboembolism with inflammatory bowel disease. Clin Appl Thromb Hemost (2010) 0.97
Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Intern Med (2007) 0.97
Vascular endothelial growth factors in cardiovascular medicine. J Cardiovasc Med (Hagerstown) (2008) 0.97
Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. J Atheroscler Thromb (2005) 0.96
Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis (2013) 0.96
Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J Gastroenterol (2011) 0.95
Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci (2005) 0.95
Systemic Toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease. Inflamm Bowel Dis (2010) 0.95
Arterial stiffness is increased in patients with inflammatory bowel disease. J Hypertens (2012) 0.95
Early atherosclerosis in patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci (2006) 0.94
Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol (2010) 0.93
Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. Clin Pharmacol Ther (2007) 0.93
The heart and the gut. Eur Heart J (2013) 0.91
C-reactive protein and atherothrombosis: Cause or effect? Blood Rev (2012) 0.90
Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol (2013) 0.90
Homocysteine, cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with inflammatory bowel disease. Dig Dis Sci (2003) 0.89
Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis (2010) 0.89
Modulation of endotoxin-induced endothelial cell toxicity by low density lipoprotein. Lab Invest (1986) 0.88
Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells. J Surg Res (2011) 0.88
Is there an association between inflammatory bowel diseases and carotid intima-media thickness? Preliminary data. Angiology (2013) 0.87
The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis. Immunopharmacol Immunotoxicol (2011) 0.87
Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J Crohns Colitis (2011) 0.87
Are patients with inflammatory bowel disease at increased risk of coronary artery disease? Am J Med (2012) 0.85
Plasma total homocysteine in the active stage of ulcerative colitis. J Gastroenterol Hepatol (2006) 0.83
Intima-media thickness of the common carotid artery is not significantly higher in Crohn's disease patients compared to healthy population. Dig Dis Sci (2010) 0.82
Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum (2014) 0.81
Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. Arch Intern Med (2002) 0.80
Endothelial dysfunction in patients with ulcerative colitis. Inflamm Bowel Dis (2006) 0.80
Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. Angiology (2013) 0.79
Lipopolysaccharide enhances oxidative modification of low density lipoprotein by copper ions, endothelial and smooth muscle cells. Atherosclerosis (1999) 0.78
Dyslipidemia and inflammation in patients with inflammatory bowel disease. Dig Dis Sci (2013) 0.76
The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest (2005) 3.99
Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med (2006) 2.33
Human endothelial cells of the placental barrier efficiently deliver cholesterol to the fetal circulation via ABCA1 and ABCG1. Circ Res (2009) 1.74
Uremia alters HDL composition and function. J Am Soc Nephrol (2011) 1.55
E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther (2013) 1.28
Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal (2011) 1.27
Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta (2006) 1.22
Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res (2012) 1.11
Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. Antioxid Redox Signal (2012) 1.02
Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys (2005) 1.01
Aging affects high-density lipoprotein composition and function. Biochim Biophys Acta (2013) 0.98
Cyanate is a novel inducer of endothelial icam-1 expression. Antioxid Redox Signal (2011) 0.96
Association between higher plasma lutein, zeaxanthin, and vitamin C concentrations and longer telomere length: results of the Austrian Stroke Prevention Study. J Am Geriatr Soc (2014) 0.93
The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol (2010) 0.93
A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther (2013) 0.93
Stomach-brain communication by vagal afferents in response to luminal acid backdiffusion, gastrin, and gastric acid secretion. Am J Physiol Gastrointest Liver Physiol (2003) 0.92
EP4 receptor stimulation down-regulates human eosinophil function. Cell Mol Life Sci (2011) 0.92
Microwave-assisted high-throughput acid hydrolysis in silicon carbide microtiter platforms--a rapid and low volume sample preparation technique for total amino acid analysis in proteins and peptides. J Chromatogr A (2010) 0.89
Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. Drug News Perspect (2009) 0.89
Endothelium-derived prostaglandin I(2) controls the migration of eosinophils. J Allergy Clin Immunol (2010) 0.88
Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking. J Allergy Clin Immunol (2012) 0.88
A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharmacology (2013) 0.86
Redox state of human serum albumin in terms of cysteine-34 in health and disease. Methods Enzymol (2010) 0.85
O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms. J Mol Med (Berl) (2012) 0.83
Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors. Eur J Immunol (2011) 0.83
Metabolomics: is it useful for inflammatory bowel diseases? Curr Opin Gastroenterol (2013) 0.82
Impaired capacity of acute-phase high density lipoprotein particles to deliver cholesteryl ester to the human HUH-7 hepatoma cell line. Int J Biochem Cell Biol (2002) 0.82
The myeloperoxidase product hypochlorous acid generates irreversible high-density lipoprotein receptor inhibitors. Arterioscler Thromb Vasc Biol (2013) 0.82
Distinct composition of human fetal HDL attenuates its anti-oxidative capacity. Biochim Biophys Acta (2013) 0.81
Immunocytochemical characterization of rat brainstem neurons with vagal afferent input from the stomach challenged by acid or ammonia. Eur J Neurosci (2004) 0.81
Fetal HDL/apoE: a novel regulator of gene expression in human placental endothelial cells. Physiol Genomics (2011) 0.79
Phospholipid transfer protein in the placental endothelium is affected by gestational diabetes mellitus. J Clin Endocrinol Metab (2011) 0.79
A biased non-Gαi OXE-R antagonist demonstrates that Gαi protein subunit is not directly involved in neutrophil, eosinophil, and monocyte activation by 5-oxo-ETE. J Immunol (2014) 0.79
HDL Cholesterol Efflux Capacity and Cardiovascular Events in Patients With Chronic Kidney Disease. J Am Coll Cardiol (2017) 0.76
The EP3 Agonist Sulprostone Enhances Platelet Adhesion But Not Thrombus Formation Under Flow Conditions. Pharmacology (2015) 0.76
Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PLoS One (2012) 0.76
Correction: High-Density Lipoprotein Function in Exudative Age-Related Macular Degeneration. PLoS One (2016) 0.75
Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview. Pharmacology (2015) 0.75
Repeated subinflammatory ultraviolet B irradiation increases substance P and calcitonin gene-related peptide content and augments mustard oil-induced neurogenic inflammation in the skin of rats. Neurosci Lett (2002) 0.75